BriaCell prices best-efforts offering of 1,449,300 shares at $3.25 each, raising $4.7 million

• Briacell Therapeutics priced a best-efforts offering of 1,449,300 common shares at USD 3.25 each.
• Gross proceeds expected at about USD 4.7 million; closing set for June 2, 2026, subject to customary conditions.
• Net proceeds earmarked for working capital, general corporate purposes, business advancement.
• ThinkEquity acting as sole placement agent.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-026953), on June 03, 2026, and is solely responsible for the information contained therein.